Cannabis and JZL184
Browse the latest research linking medical marijuana / medicinal cannabis and JZL184 (a cannabinoid (synthetic))

Action: 2-AG booster
JZL184 is an irreversible inhibitor for monoacylglycerol lipase (MAGL), the primary enzyme responsible for degrading the endocannabinoid 2-arachidonoylglycerol (2-AG). [Wikipedia]
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
O-1966, PF3845, JZL184, WWL70 TBI,anti-inflamatory in mice via review Endocannabinoids: A Promising Impact for Traumatic Brain Injury Feb 2017
Action Pathway: CB1,CB2
TBI-induced behavioral deficits, such as learning and memory, neurological motor impairments, post-traumatic convulsions or seizures, and anxiety also respond to manipulations of the endocannabinoid system. As such, the endocannabinoid system possesses potential drugable receptor and enzyme targets for the treatment of diverse TBI pathology.
Back to Knowledge Base